---
title: "Medicus Pharma (MDCX) news: delisting, going concern and merger"
url: "https://aibio.space/companies/medicus-pharma/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "MDCX delisting, going concern and merger news: Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter. Medicus Pharma Ltd."
---

MDCX Medicus Pharma Ltd. NASDAQ · Canada

# Medicus Pharma (MDCX) news MDCX delisting, going concern and merger news

Listings · 2026-10-23

## [Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter](https://aibio.space/news/medicus-pharma-regains-nasdaq-1-00-bid-price-compliance-days-after/)

Nasdaq closed Medicus Pharma's bid price case on October 23, 2026, three days after a delisting letter. The 8-K does not say whether the company now meets the $5 million stockholders' equity standard Nasdaq cited.

## Latest Medicus Pharma news

1. 2026-05-27 Debt Financing [Medicus Pharma closes secured notes with Streeterville Capital](https://aibio.space/news/medicus-pharma-closes-secured-notes-streeterville-capital/) The lender paid $12 million at closing and deposited $10 million in a subsidiary's account under a deposit account control agreement. The notes carry monthly cash redemptions and trigger-based increases.
2. 2025-10-17 Financings [Medicus Pharma sells 1,088,048 shares to Yorkville under standby equity purchase agreement](https://aibio.space/news/medicus-pharma-sells-1-088-048-shares-yorkville-under-standby-equity/) Medicus Pharma (Nasdaq: MDCX) sold shares in eight transactions between September 8 and October 16, 2025 for approximate aggregate consideration of $2,526,364. It used part to prepay a Yorkville debenture.
3. 2025-09-18 Debt Financing [Medicus Pharma issues $8.0 million debenture to Yorkville fund](https://aibio.space/news/medicus-pharma-issues-8-0-million-debenture-yorkville-fund/) The 8% debenture matures in twelve months and refinances about $1.7 million of earlier Yorkville debentures. Medicus expects net proceeds of approximately $5.7 million, and the lender can require repayment from part of any equity raise.
4. 2025-09-02 Mergers [Medicus Pharma completes Antev acquisition for about US$3.0 million cash and 1,603,164 shares](https://aibio.space/news/medicus-pharma-completes-antev-acquisition-about-us-3-0-million-cash-1/) Medicus closed its Antev deal on August 29, 2025 and could owe up to approximately $65 million more on milestones. It also sold 250,000 shares to Yorkville for approximately $490,535 and added Patrick J. Mahaffy to its board.
5. 2025-06-30 Mergers [Medicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million](https://aibio.space/news/medicus-pharma-agrees-buy-antev-2-666-600-shares-plus-up-us-65-million/) Antev shareholders would receive about 17% of Medicus common shares, plus up to US$65 million in contingent payments tied to FDA milestones. Antev's lead drug missed a secondary endpoint in an earlier Phase 2a trial, and Medicus carries going-concern doubt.

## Medicus Pharma at a glance

- **Ticker**: MDCX

- **Listing**: NASDAQ

- **Country**: Canada

- **Cash, Jun 30, 2026**: $15.2 million

### Related companies

- [Medicenna Therapeutics](https://aibio.space/companies/medicenna-therapeutics/) TSX: MDNA
- [Microbix Biosystems](https://aibio.space/companies/microbix-biosystems/) TSX: MBX
- [ME Therapeutics Holdings](https://aibio.space/companies/me-therapeutics/) CSE: METX
- [Aurinia Pharmaceuticals](https://aibio.space/companies/aurinia-pharmaceuticals/) NASDAQ: AUPH
- [Quantum Biopharma](https://aibio.space/companies/quantum-biopharma/) NASDAQ: QNTM
- [Sernova Biotherapeutics](https://aibio.space/companies/sernova-biotherapeutics/) TSX: SVA
- [ProMIS Neurosciences](https://aibio.space/companies/promis-neurosciences/) NASDAQ: PMN
- [DiagnaMed Holdings](https://aibio.space/companies/diagnamed/) CSE: DMED

### Also on NASDAQ

- [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) COGT
- [ProMIS Neurosciences](https://aibio.space/companies/promis-neurosciences/) PMN
- [Aspire-Lakewood Holdings](https://aibio.space/companies/aspire-lakewood/) ASBP
- [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) INM
- [PDS Biotechnology](https://aibio.space/companies/pds-biotechnology/) PDSB
- [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) ANTX

## Medicus Pharma annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$7.7 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) |
| Net income (loss) | [-$47.3 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) |
| Cash from operations | [-$22.8 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) | [-$10.2 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) |
| Cash and equivalents | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004230/) | [$4.2 million](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001606/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $15.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Medicus Pharma

Was Medicus Pharma delisted?

Our latest story on this, dated Oct 23, 2026: "Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/medicus-pharma-regains-nasdaq-1-00-bid-price-compliance-days-after/).

Has Medicus Pharma issued a going-concern warning?

Our latest story on this, dated Jun 30, 2025: "Medicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/medicus-pharma-agrees-buy-antev-2-666-600-shares-plus-up-us-65-million/).

Is Medicus Pharma involved in a merger or acquisition?

Our latest story on this, dated Jun 30, 2025: "Medicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/medicus-pharma-agrees-buy-antev-2-666-600-shares-plus-up-us-65-million/).

What is the ticker symbol of Medicus Pharma?

Medicus Pharma Ltd. trades under the ticker MDCX on NASDAQ.

Where is Medicus Pharma listed?

Medicus Pharma Ltd. is listed on NASDAQ.

What is the SEC CIK of Medicus Pharma?

The SEC Central Index Key (CIK) for Medicus Pharma Ltd. is 1997296. Its filings are on SEC EDGAR.

How many shares does Medicus Pharma have outstanding?

63,180,610 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is Medicus Pharma listed under?

Our directory records Medicus Pharma Ltd. under Canada.

What does Medicus Pharma do?

Our directory classifies Medicus Pharma Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Medicus Pharma?

The ISIN recorded for Medicus Pharma Ltd. is CA58471K3010.

Does aibio.space cover Medicus Pharma?

aibio.space lists Medicus Pharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Medicus Pharma incorporated?

SEC records list its state or country of incorporation as A6.

Is Medicus Pharma profitable?

Medicus Pharma Ltd. reported a net loss of $47.3 million for the fiscal year ended Dec 31, 2025, and used $22.8 million of cash in operations, per its annual report to the SEC.

How much does Medicus Pharma spend on research and development?

$7.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Medicus Pharma have?

$15.2 million in cash at Jun 30, 2026, per its 10-Q.

## Investor discussion: Medicus Pharma

Members talk about Medicus Pharma (MDCX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Medicus Pharma, newest first. Each line links the filing it comes from.

1. 2026-10-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326005528/form8k.htm)
2. 2026-10-16 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326005382/form8k.htm)
3. 2026-10-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326005226/form8k.htm)
4. 2026-09-14 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004906/form8k.htm)
5. 2026-09-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004898/form8k.htm)
6. 2026-05-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/form8k.htm)
7. 2026-05-04 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326002277/formdef14a.htm)
8. 2026-04-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326002142/form8k.htm)
9. 2026-04-21 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326002062/formpre14a.htm)
10. 2026-03-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326001326/form8k.htm)
11. 2026-01-30 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299326000505/forms3.htm)
12. 2025-12-30 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325017488/forms3.htm)
13. 2025-12-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325017219/exhibit99-1.htm)
14. 2025-10-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325016179/form8k.htm)
15. 2025-09-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/exhibit99-1.htm)
16. 2025-09-02 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325015149/exhibit99-1.htm)
17. 2025-08-22 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/exhibit99-1.htm)
18. 2025-07-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325013073/exhibit99-1.htm)
19. 2025-06-30 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/exhibit99-1.htm)
20. 2025-06-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325011991/0001062993-25-011991-index-headers.html)
21. 2025-06-05 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325011051/form8k.htm)
22. 2025-05-27 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325010394/forms1.htm)
23. 2025-05-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325008436/form8k.htm)
24. 2025-03-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325006485/form10k.htm)
25. 2025-02-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/exhibit99-1.htm)
26. 2024-11-25 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1997296/000106299324019596/exhibit99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MDCX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MDCX/).

## SEC filings and registration

- **SEC name**: Medicus Pharma Ltd.

- **CIK**: 1997296

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: MDCX (Nasdaq), MDCXW (Nasdaq)

- **State or country of incorporation**: A6

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN, PA, 19428

- **Phone**: 610-540-7515

- **Shares outstanding**: 63,180,610 as of 2026-08-10 (10-Q filed 2026-08-12)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326005382/form8k.htm) filed 2026-10-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326005226/form8k.htm) filed 2026-10-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004906/form8k.htm) filed 2026-09-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004898/form8k.htm) filed 2026-09-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm) filed 2026-09-03
- [10-Q](https://www.sec.gov/Archives/edgar/data/1997296/000106299326004230/form10q.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326003060/form8k.htm) filed 2026-06-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/form8k.htm) filed 2026-05-27

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001997296), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Medicus Pharma Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MDCX, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Medicus Pharma Ltd.

- **Ticker**: MDCX

- **Listing**: NASDAQ

- **Country or territory**: Canada

- **Business scope**: Biotechnology

- **ISIN**: CA58471K3010

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MDCX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/medicus-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Medicus Pharma (MDCX) news: delisting, going concern and merger", 2026-10-31, https://aibio.space/companies/medicus-pharma/